Joel Schneider is the founder of Solid Biosciences. Latest round: Series C. Backed by RA Capital Management, Bain Capital Life Sciences, RTW Investments.
Joel Schneider was the Chief Operating Officer at Solid Biosciences, a life sciences company targeting therapies for Duchenne muscular dystrophy. He worked at the company for eight years in various roles. He departed Solid Biosciences in May 2022 to become the CEO of a privately held, viral-based gene therapy platform company.
Full founder directory · Investor directory · Company funding database · Fundraising library